Predictions
Merck & Co. Inc.
Start price
Target price
Perf. (%)
€100.60
08.11.22
08.11.22
€150.00
31.01.25
31.01.25
5.77%
05.05.23
05.05.23
Could be worthwhile Investment >10% per year
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€370.05
04.11.22
04.11.22
€610.00
04.11.23
04.11.23
44.17%
05.11.23
05.11.23
Top 10 in its market
Could be worthwhile Investment >10% per year
High dividend yield expected
Innovative
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€758.30
01.11.22
01.11.22
€900.00
01.11.23
01.11.23
-9.34%
05.05.23
05.05.23
Could be very worthwhile Investment >20% year
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€362.80
29.10.22
29.10.22
€400.00
29.10.23
29.10.23
6.95%
05.05.23
05.05.23
Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€316.75
29.10.22
29.10.22
-
29.11.22
29.11.22
-3.65%
30.11.22
30.11.22
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€78.68
28.10.22
28.10.22
-
28.10.23
28.10.23
-7.17%
18.05.23
18.05.23
Risky Investment
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€301.55
28.10.22
28.10.22
-
28.10.23
28.10.23
-10.79%
01.01.23
01.01.23
Risky Investment
Viatris Inc.
Start price
Target price
Perf. (%)
€9.76
18.10.22
18.10.22
-
18.11.26
18.11.26
13.97%
11.03.24
11.03.24
Probably not worthwhile Investment
Pfizer Inc.
Start price
Target price
Perf. (%)
€44.90
18.10.22
18.10.22
-
18.11.26
18.11.26
-44.54%
11.03.24
11.03.24
Probably not worthwhile Investment
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€67.38
13.10.22
13.10.22
€46.00
13.10.23
13.10.23
9.44%
14.10.23
14.10.23
Top 10 in its market
Good rating
Medium risks for its business
Bad culture
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€60.80
13.10.22
13.10.22
-
-
13.10.22
13.10.22
Top 10 in its market
Good rating
Medium risks for its business
Bad culture
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€338.70
07.10.22
07.10.22
€350.00
07.10.23
07.10.23
7.12%
29.10.22
29.10.22
Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
Biogen Inc.
Start price
Target price
Perf. (%)
€272.50
30.09.22
30.09.22
€400.00
31.12.24
31.12.24
4.59%
05.05.23
05.05.23
Could be very worthwhile Investment >20% year